Earnings were good to a few health companies, such as Immucor ( BLUD), but not as nice to others on a gloomy Thursday in the market. Immucor reported net income of $18.2 million, up 51% from $12.1 million for the same quarter last year. The company said it earned 26 cents a share. The Thomson Financial consensus target was 22 cents a share. The company gained $2.05, or 7.2%, to $30.63. Also up, Affymetrix ( AFFX) reported earnings after market close on Wednesday. The company said revenue rose 10% to $88.3 million, and it reported net income of $1.2 million, or 2 cents a share, compared with a loss of $10.1 million, or 15 cents a share, during the same period in 2006. Looking ahead, Affymetrix is predicting revenue from $365 million to $385 million for fiscal 2007, and gross margins around 60%. Shares climbed $1.44, or 5.8%, to $26.30. But on the down side, Bristol-Myers Squibb ( BMY) earned 37 cents a share, excluding one-time items, which is one penny better than the consensus of analysts polled by Thomson First Call. Revenue of $4.93 billion matched expectations. The company raised guidance for the year, but investors seemed dissatisfied -- shares fell $1.33, or 4.2%, to $30.25. Bristol-Myers Squibb and AstraZeneca are both components of the Amex Pharmaceutical index, which was down 9.42, or 2.8%, to 340.44.
Stocks soar as the gross domestic product rises at an annualized rate of 3.5% in the third quarter and continuing jobless claims fall. Gregg Greenberg recaps the action in The Real Story video (above).